S2Medical (S2M) Q2 2024 earnings summary

Executive summary

• Net sales for Q2 2024 increased to 2.9 MSEK from 2.7 MSEK year-over-year, driven by higher sales linked to the Abena partnership and Epiprotect technology sales.

• Operating expenses decreased significantly due to efficiency improvements in personnel and external costs.

• Net income for Q2 2024 was 6.9 MSEK, compared to -8.3 MSEK in Q2 2023, supported by cost reductions and one-time income from Epiprotect technology sales.

• The company successfully completed its reconstruction process and is now debt-free.

• Acquisition of a 22.3% stake in Eyracure AB post-period strengthens growth prospects.

Financial highlights

• Q2 2024 net sales: 2.9 MSEK (Q2 2023: 2.7 MSEK).

• Operating income: 7.0 MSEK (Q2 2023: -5.1 MSEK).

• Net income: 6.9 MSEK (Q2 2023: -8.3 MSEK).

• Earnings per share: 0.02 SEK (Q2 2023: -0.26 SEK).

• Cash and cash equivalents at period end: 1.4 MSEK, unchanged from period start.

Outlook and guidance

• Management expects to achieve positive cash flow soon, supported by ongoing efficiency and strategic investments.

• Continued focus on innovation and global distribution partnerships to drive future growth.